Nicotine’s plasma half-life averages about two hours, but that number explains the tail of a pouch and not the peak. No regulator, manufacturer or registered trial has published a spacing interval, a daily maximum or a dosing rule for nicotine pouches. The only published intervals belong to a different product class, and the only pouch timing figures in the literature are trial washouts designed to clear nicotine out.
Half-life is the number people reach for when they want to know how far apart to put pouches, and it is the wrong number for the job. I want to set out what it actually is, what the measurements in pouch users actually show, and where the published guidance stops — because it stops much earlier than most of the internet suggests.
There are three nicotine half-lives, not one
The reference compilation is Benowitz, Hukkanen and Jacob’s chapter in Handbook of Experimental Pharmacology (2009), which is openly deposited and was funded by the National Institute on Drug Abuse — the acknowledgement reads “Much of the research described in this chapter was supported by US Public Health Service grants DA02277 and DA12393 from the National Institute on Drug Abuse, National Institutes of Health”. No industry money. It gives three different half-lives for the same molecule:
- “The distribution half-life averages about 8 min.” — the phase where nicotine moves out of blood into tissue.
- “The plasma half-life of nicotine after intravenous infusion or cigarette smoking averages about 2 h.” — the figure everybody quotes.
- “the terminal half-life averages 11 h” — measured by urinary excretion, and the one almost nobody mentions. The paper explains it as “The longer half-life detected at lower concentrations of nicotine is most likely a consequence of slow release of nicotine from body tissues.”
Cotinine, nicotine’s main metabolite and the marker used in most exposure studies, is slower again: levels “decline in a log linear fashion with an average half-life of about 16 h.” The chapter’s own biomarker table gives nicotine as 1–2 h and cotinine as 16–18 h, so if you see 16 or 18 quoted for cotinine, both come from the same source and refer to slightly different things. Nicotine’s total clearance averages about 1,200 mL/min and its steady-state volume of distribution about 2.6 L per kg.
The practical point: if you read “two hours” and conclude the nicotine from a pouch is gone in an afternoon, you have used the plasma figure where the terminal figure applies. The two-hour number describes how fast the concentration falls from a peak. It does not describe when the molecule has left you.
Your half-life is not the average, and the spread is large
Clearance is set mostly by the liver enzyme CYP2A6, and the same chapter is blunt about how badly genotype predicts it: “there is wide variability in nicotine clearance among people with wild-type CYP2A6 genes”, and “only a small proportion of the genetic variability in nicotine clearance can be explained by known CYP2A6 gene variants”. The usable marker is a phenotype, not a gene test — “The 3′-hydroxycotinine/cotinine ratio (3HC/cotinine) in plasma and saliva has been evaluated as a non-invasive probe for CYP2A6 activity”.
Documented sources of variation, all from the same compilation:
- Sex: “Nicotine clearance and cotinine clearance were 13 and 24% higher, respectively, in women not using oral contraceptives than in men.”
- Oral contraceptives: “Oral contraceptive use induced increases in nicotine and cotinine clearance by 28 and 30%, respectively”.
- Ancestry: “The total and nonrenal clearance of cotinine was significantly lower in blacks than in whites”, and the urinary 3HC/cotinine ratio “was higher in whites and Hispanics than in blacks and Asians”.
- Age in adults: none. “No differences in steady-state nicotine plasma levels or estimated plasma clearance values were detected in three age groups (18–39, 40–59, and 60–69 years)”.
Cotinine clearance alone has a “usual clearance range 20–75 ml min” per minute across individuals — a 3.75-fold spread. I wouldn’t put much faith in any schedule derived from a single population average when the population varies by that much.
What accumulates over a day — measured in smokers, not in pouch users
This is the part of the half-life story that actually matters, and the only good measurements are in cigarette smokers. State that limitation before using any of it. Benowitz and colleagues set out the prediction and then the confirmation:
“Based on a half-life of 2 h for nicotine, one would predict accumulation over 6–8 h (3–4 half-lives) of regular smoking” “and persistence of significant levels for 6–8 h after cessation of smoking.” “If a smoker smokes until bedtime, significant levels should persist all night.”
And the observed behaviour: “Peak and trough levels follow each cigarette, but as the day progresses, trough levels rise”, so that smoking “represents a multiple dosing situation with considerable accumulation while smoking” “and persistent levels for 24 h of each day.”
The numbers are more persuasive than the sentences. In regular smokers, “Typical trough concentrations during daily smoking range between 10 and 37 ng ml” per millilitre and “typical peak concentrations range between 19 and 50 ng ml” per millilitre. Look at the overlap: the trough ceiling of 37 sits well above the peak floor of 19. By the afternoon, the baseline is doing most of the work and each individual dose is doing less. That is what a two-hour half-life plus repeated dosing produces, and it is why “it wears off in two hours” feels wrong to anyone who uses nicotine all day.
One caveat I have to print rather than bury: abstinence speeds clearance up — “After 4 days of smoking abstinence, nicotine clearance was increased by 14%” and “after 7 days of abstinence, nicotine clearance was 36% higher” — but the chapter attributes that to constituents of tobacco smoke inhibiting metabolism. There is no reason to assume it transfers to a smoke-free product, and no one has measured whether it does.
The pouch numbers: time to peak tracks how long it is in your lip
The best single pharmacokinetic dataset on pouches is McEwan and colleagues, European Journal of Drug Metabolism and Pharmacokinetics (2022), a randomised study in 35 habitual users. It is industry work and the funding line is unambiguous: “The study was supported by British American Tobacco (Investments) Limited, the manufacturer of Lyft and Velo smokeless oral nicotine pouches.” All the authors were BAT employees or contractors. Treat the measurements as measurements and the framing as the sponsor’s.
Each product was used for 60 minutes, after at least 12 hours’ abstinence, with blood sampled out to 360 minutes.
| Product | Nicotine per pouch | Cmax (ng/mL) | Tmax (min) | Elimination half-life (h) |
|---|---|---|---|---|
| Cigarette (comparator) | n/a | 13.9 | 7 | 2.3 |
| Lyft NP | 10 mg | 17.1 | 60 | 2.2 |
| Nordic Spirit NP | 9 mg | 18.4 | 62 | 2.2 |
| On! NP | 6 mg | 17.5 | 65 | 2.2 |
| Skruf NP | 8 mg | 13.0 | 60 | 2.2 |
| Zyn NP | 10 mg | 11.9 | 65 | 2.8 |
Three things fall out of that table.
First, the half-life column is almost flat. The paper reports that “values for the NPs used in this study ranged from 2.2 to 2.8” hours, and that this was “in line with the reported nicotine plasma elimination half-life”. The 2.8 for Zyn is not a product property, and the authors say so: there was more variability in the half-life “for Zyn, based on an inexplicably high result from one subject.” So once a pouch is out of your lip, the decline you see is ordinary nicotine elimination, at roughly the same rate for every product.
Second, the milligram number on the can did not predict the peak. “Plasma nicotine concentration was not associated with the nicotine contents of the NPs.” A 6 mg pouch out-delivered a 10 mg pouch on both peak concentration and total exposure. I have written about this at length in the complete mg guide; it is the single most reliable finding in the pouch literature.
Third, and this is the spacing answer hiding in plain sight: time to peak was 60 to 65 minutes for every pouch, against 7 minutes for a cigarette — and the pouches were used for 60 minutes. The peak arrived when the pouch came out.
Azzopardi and colleagues, Journal of Clinical Pharmacology (2026), tested that directly. It is also BAT work — “This study was funded by BAT (Investments) Ltd.”, and “At the time the study was conducted, all authors were employees of BAT, which was the sponsor and funding source of this study.” The same 35 participants used 11 mg and 20 mg pouches for 10, 20 and 30 minutes. Median time to peak came in at 0.17 h, 0.33 h and 0.50 h — ten, twenty and thirty minutes. The conclusion is one line: “Nicotine delivery to the consumer increases with the duration of use.”
Across those two studies, use duration ranges from ten minutes to an hour, and time to peak follows it almost exactly, while the half-life stays at about 2.2 hours throughout. Half-life is a constant of the person. Time to peak is a function of how long you leave the pouch in.
Half-life explains the tail; duration explains the peak
A 2026 review in Materials by Håkan Engqvist makes the same point explicitly, and I should say up front that the author is a shareholder in a pouch-technology company: the paper states “This work was supported by Emplicure AB.” and “H.E. is a shareholder in Emplicure AB, which develops nicotine pouch technologies including calcium sulfate-based carrier systems.” I am using it because the arithmetic above already supports the point, not as the basis for it.
Its section on elimination half-life says: “Importantly, elimination half-life is largely independent of pouch formulation.” And then the sentence that reframes the whole question — “the apparent pharmacokinetic profile observed following pouch use reflects the interaction between nicotine elimination and ongoing absorption from the pouch.” In slow-releasing products, “absorption may continue for a substantial portion of the elimination phase”.
The same review names the mistake most strength tables make: “A common misconception is that nicotine pharmacokinetics can be predicted directly from nicotine content.” It argues that “the concentration of free-base nicotine rather than the total nicotine concentration is often the most important determinant of nicotine absorption rate”, and that “Two products containing identical amounts of nicotine may therefore produce substantially different pharmacokinetic profiles if their pH values differ”.
For comparison, the nicotine patch genuinely does hide its half-life. Two independent papers describe patch kinetics as flip-flop — the apparent half-life is skin desorption, not elimination. A pouch is different because you remove it: input stops, and the measured 2.2-hour decline in pouch users is real elimination. That distinction is mine, reasoned from the figures above rather than quoted from anyone, and it is the reason the half-life is nearly irrelevant while the pouch is in and exactly right once it is out.
The only published dosing intervals belong to a different product class
There is one place where a US authority has approved an explicit interval for an oral nicotine product, and it is not a pouch. The over-the-counter nicotine polacrilex lozenge is an approved drug, and its FDA-approved label sets out a twelve-week schedule. Its stated purpose is “Stop smoking aid” and its use is “reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking”.
| Weeks 1 to 6 | Weeks 7 to 9 | Weeks 10 to 12 | |
|---|---|---|---|
| Lozenge | 1 lozenge every 1 to 2 hours | 1 lozenge every 2 to 4 hours | 1 lozenge every 4 to 8 hours |
| Gum | 1 piece every 1 to 2 hours | 1 piece every 2 to 4 hours | 1 piece every 4 to 8 hours |
A note on quoting that table: in the lozenge label the interval is split across two separate elements, so “1 lozenge every” and “1 to 2 hours” are two fragments of one printed cell. The gum label writes “1 piece every 1 to 2 hours” as one string. The intervals are identical; the caps are not. The lozenge says “do not use more than 5 lozenges in 6 hours. Do not use more than 20 lozenges per day.” and “do not use more than one lozenge at a time or continuously use one lozenge after another”. The gum says “do not use more than 24 pieces a day” and, unlike the lozenge, permits a second: “if you experience strong or frequent cravings, you may use a second piece within the hour.”
What the label does not contain is any pharmacokinetic justification. There is no half-life, no peak concentration and no PK section anywhere in it. The interval is asserted as a condition of an approved application, not derived from a curve — which is worth knowing before anyone transplants it onto a product it was never written for. A nicotine pouch is not a lozenge, carries no indication, and may not claim one; I set the regulatory difference out in full in nicotine pouches vs nicotine lozenges.
What nobody has published for pouches
I went looking for a pouch interval from any authority and found nothing, three independent ways.
FDA’s authorised list says nothing about use. The page listing every nicotine pouch product that may lawfully be sold in the United States — “There are 67 nicotine pouch products authorized by the FDA.”, content current 30 October 2026 — contains zero occurrences of “dose”, “dosing”, “interval”, “per day”, “maximum” or even “hours”. It authorises products; it does not tell anyone how to use them. FDA’s own framing of what authorisation means is worth reproducing in full, because it is routinely truncated: “While these products are authorized to be sold in the United States,” “it does not mean these products are safe, nor are they “FDA approved.”” “All tobacco products are harmful and potentially addictive.” “Those who do not use tobacco products shouldn’t start.”
The clinical trials registry has never published one either. Querying ClinicalTrials.gov for “nicotine pouch” returns 53 registered studies. Searching all 53 full records for interval language produces plenty of matches and not one recommendation: they are eligibility criteria, questionnaire timings, protocol washouts and study-duration caps. Two traps are worth naming because they look exactly like the answer. McEwan’s study describes “A minimum familiarisation period of 30” minutes per product “with a gap of 1–2” hours between products — that is a Day −1 tolerance step, not a dosing interval, and it was not applied in the PK sessions at all. And one registered trial caps familiarisation at “no more than 3 pouches” on day one. Neither is guidance.
The only authority-grade numbers attached to pouch timing are washouts, and they all run the wrong way. McEwan required “at least 12” hours’ abstinence; Azzopardi used “A period of at least 24 h between the start of each product use session” plus “a minimum 12” hours off nicotine. Those intervals exist to clear nicotine out of a participant, which is the opposite of a usage schedule — but they are the only published pouch intervals that exist.
The study designed to answer the accumulation question does exist, and it has not started. NCT07829939, Clinical Pharmacology of Oral Nicotine Pouches, University of California San Francisco, was first posted on 21 September 2026: a Phase 1 randomised crossover in 24 people, four separate eight-hour days, placebo and 3 mg and 6 mg pouches against the participant’s own cigarettes or e-cigarette. Its hypothesis is exactly the question this article cannot answer: “With multiple use of oral nicotine pouches (ONPs) throughout the day, participants will adjust their intake of nicotine to be similar to or higher than that seen with cigarette smoking or vaping.” Status, as of today: not yet recruiting. Estimated primary completion: October 2029.
So what does the half-life actually tell you?
It tells you three things, and refuses to tell you a fourth.
It tells you that the fall after a pouch comes out is ordinary nicotine elimination at roughly 2.2 hours, the same for every product measured. It tells you that repeated dosing through a day accumulates — demonstrated in smokers, with trough and peak ranges that overlap heavily by the afternoon, and never measured in pouch users. And it tells you that the thing varying most between two people on the same product is not the product: clearance differs by a factor of three or more across individuals, and no gene test resolves it.
What it does not tell you is how far apart to use pouches, because the peak is set by how long the pouch is in rather than by elimination, and because no authority, manufacturer or completed trial has published an interval. Anyone who gives you a number for pouches has made it up or borrowed it from a drug label written for a different product. I would rather say that plainly than invent a schedule, and I will update this page when NCT07829939 reports.
FAQ
How long does nicotine stay in your system after a pouch?
There is no single answer, because there are three half-lives. The plasma concentration falls with a half-life of about 2.2 hours in measured pouch users. The terminal half-life, from urinary excretion, averages about 11 hours. Cotinine, the metabolite most tests look for, averages about 16 hours.
Does a stronger pouch last longer?
On the published measurements, no — and it does not necessarily hit harder either. Peak concentration was not associated with the milligram figure on the can, and the elimination half-life was essentially identical across a 6 mg to 10 mg range.
Why do I feel a pouch wearing off long before two hours?
Because the peak arrives when the pouch comes out, not two hours later. In the measured studies, time to peak tracked use duration from ten minutes to sixty. What you notice is the end of absorption, not the half-life.
Can I use the lozenge’s one-to-two-hour interval for pouches?
That interval is a condition of an approved drug application for a different product, with its own daily cap and its own indication, and its label contains no pharmacokinetic reasoning at all. Nothing published applies it to pouches.
Has anyone measured what happens over a full day of pouch use?
Not yet. Every published pouch pharmacokinetic study used a single timed session after overnight abstinence, and McEwan’s paper says so directly: “product use was limited to a single time-controlled use of an NP product on a single day” and “we cannot infer whether nicotine pharmacokinetics will change over time following continued use”. The trial built to answer it reports in 2029.
Sources
- Benowitz NL, Hukkanen J, Jacob P III. Nicotine Chemistry, Metabolism, Kinetics and Biomarkers. Handbook of Experimental Pharmacology, 2009. NIDA-funded. PMC2953858. Read 7 November 2026.
- McEwan M, Azzopardi D, Gale N, Camacho OM, Hardie G, Fearon IM, Murphy J. A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette. Eur J Drug Metab Pharmacokinet, 2022. Funded by British American Tobacco (Investments) Limited; all authors BAT employees or contractors. PMC8917032. Read 7 November 2026.
- Azzopardi D, Brown E, Meichanetzidis F, Fiebelkorn S, Haswell LE, Hardie G, McEwan M. A Randomized Crossover Clinical Study to Assess the Effect of Oral Nicotine Pouches Used for Different Durations on Plasma Nicotine Pharmacokinetics in Healthy Oral Pouch Consumers. J Clin Pharmacol 66(1):e70090, 2026. Funded by BAT (Investments) Ltd. PMC12709140. Read 7 November 2026.
- Engqvist H. The Physicochemical Principles Governing Nicotine Delivery from Oral Nicotine Pouches. Materials, 2026. Supported by Emplicure AB; the author is a shareholder in that company. PMC13707332. Read 7 November 2026.
- NICORETTE (nicotine polacrilex) lozenge, prescribing information, Haleon US Holdings LLC, ANDA 077007, effective 25 April 2025. DailyMed setid ffeb8286-860d-49f5-8df3-724afb4aaad8. Read 7 November 2026.
- NICORETTE FRUIT CHILL (nicotine polacrilex) chewing gum, Haleon US Holdings LLC, NDA 018612 and NDA 020066. DailyMed setid a0206139-59c6-44c3-963c-8cb5f2d69075. Read 7 November 2026.
- US Food and Drug Administration. Nicotine Pouch Products Authorized by the FDA. Content current 30 October 2026. fda.gov. Read 7 November 2026.
- ClinicalTrials.gov API v2, query term “nicotine pouch”, 53 registered studies. clinicaltrials.gov. Read 7 November 2026.
- Clinical Pharmacology of Oral Nicotine Pouches (NCT07829939), University of California San Francisco. First posted 21 September 2026; not yet recruiting; estimated primary completion October 2029. clinicaltrials.gov. Read 7 November 2026.
Last verified: 7 November 2026. Related reading: nicotine pouch absorption, nicotine equivalence, can you swallow snus and the master ranking. If quitting nicotine altogether is the goal, what the evidence says about quitting smoking with pouches is the more useful page. For the equivalent arithmetic on the tobacco side — how much of a portion’s nicotine actually leaves the pouch and reaches the blood — see how much nicotine is absorbed from a snus portion.
